<DOC>
	<DOCNO>NCT00265018</DOCNO>
	<brief_summary>This study design find optimum radiation dose number cycle ABVD chemotherapy combine involved field irradiation . It test whether reduction 4 2 cycle ABVD and/or reduction radiation dose 30 20 Gy feasible without loss efficacy .</brief_summary>
	<brief_title>HD10 Early Stages</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Hodgkin´s lymphoma ( histologically proven ) CS ( PS ) IA , IB , IIA , IIB without follow risk factor : 1. bulky mediastinal mass ( &gt; 1/3 maximum transverse thorax diameter ) 2. extranodal involvement 3 . ESR &gt; 50 ( A ) , &gt; 30 ( Bsymptoms ) 4 . 3 lymph node area involve write informaed consent Leukocytes &lt; 3000/microl Platelets &lt; 100000/microl Hodgkin´s Disease `` composite lymphoma '' Activity index ( WHO ) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Hodgkin´s lymphoma</keyword>
	<keyword>early stage</keyword>
</DOC>